[Reversal Effect of NVP-BEZ235 on Doxorubicin-Resistance in Burkitt Lymphoma RAJI Cell Line]

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Apr;32(2):476-482. doi: 10.19746/j.cnki.issn.1009-2137.2024.02.024.
[Article in Chinese]

Abstract

Objective: To study the reversal effect of NVP-BEZ235 on doxorubicin resistance in Burkitt lymphoma RAJI cell line.

Methods: The doxorubicin-resistant cell line was induced by treating RAJI cells with a concentration gradient of doxorubicin. The levels of Pgp, p-AKT, and p-mTOR in cells were detected by Western blot. Cell viability was detected by MTT assay. IC50 was computed by SPSS.

Results: The doxorubicin-resistant Burkitt lymphoma cell line, RAJI/DOX, was established successfully. The expression of Pgp and the phosphorylation levels of AKT and mTOR in RAJI/DOX cell line were both higher than those in RAJI cell line. NVP-BEZ235 downregulated the phosphorylation levels of AKT and mTOR in RAJI/DOX cell line. NVP-BEZ235 inhibited the proliferation of RAJI/DOX cell line, and the effect was obvious when it was cooperated with doxorubicin.

Conclusion: The constitutive activation of PI3K/AKT/mTOR pathway of RAJI/DOX cell line was more serious than RAJI cell line. NVP-BEZ235 reversed doxorubicin resistance of RAJI/DOX cell line by inhibiting the PI3K/AKT/mTOR signal pathway.

题目: NVP-BEZ235逆转伯基特淋巴瘤RAJI细胞阿霉素耐药的研究.

目的: 研究NVP-BEZ23对耐阿霉素细胞株RAJI/DOX的逆转耐药作用。.

方法: 利用浓度梯度法诱导耐阿霉素细胞株RAJI/DOX;Western blot测定各组细胞Pgp、p-AKT、p-mTOR蛋白水平;MTT法检测细胞抑制率,SPSS软件测定IC50。.

结果: 成功诱导出耐阿霉素细胞株RAJI/DOX。耐阿霉素细胞株RAJI/DOX中Pgp、p-AKT、p-mTOR蛋白水平高于亲本细胞RAJI。NVP-BEZ235可引起耐阿霉素细胞株RAJI/DOX中p-AKT、p-mTOR蛋白水平下降。NVP-BEZ235能够抑制耐阿霉素细胞株RAJI/DOX增殖,与阿霉素具有协同作用。.

结论: PI3K/AKT/mTOR通道在耐阿霉素伯基特淋巴瘤细胞中进一步活化;NVP-BEZ235通过抑制PI3K/AKT/mTOR信号通道活化,能够与阿霉素协同抑制伯基特淋巴瘤耐药细胞,逆转伯基特淋巴瘤耐药细胞对阿霉素的耐药性。.

Keywords: NVP-BEZ235; Burkitt lymphoma; doxorubicin-resistance;reversal effect.

Publication types

  • English Abstract

MeSH terms

  • Burkitt Lymphoma*
  • Cell Line, Tumor
  • Cell Proliferation* / drug effects
  • Cell Survival / drug effects
  • Doxorubicin* / pharmacology
  • Drug Resistance, Neoplasm*
  • Humans
  • Imidazoles* / pharmacology
  • Phosphatidylinositol 3-Kinases / metabolism
  • Phosphorylation
  • Proto-Oncogene Proteins c-akt* / metabolism
  • Quinolines* / pharmacology
  • Signal Transduction
  • TOR Serine-Threonine Kinases* / metabolism

Substances

  • Doxorubicin
  • Proto-Oncogene Proteins c-akt
  • Quinolines
  • TOR Serine-Threonine Kinases
  • dactolisib
  • Imidazoles
  • MTOR protein, human
  • Phosphatidylinositol 3-Kinases